Modest reduction seen in DAS28-CPR at 3 months for those receiving TOF vs ADA, but no difference seen at 9 months.
Your search for tofacitinib returned 4 results
Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
Researchers examined risk for herpes zoster infection with biologics and small molecules for IBD.
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.